A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Status:
RECRUITING
Trial end date:
2027-08-13
Target enrollment:
Participant gender:
Summary
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.